ZP4: A novel target for CAR-T cell therapy in triple negative breast cancer

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Triple-negative breast cancer (TNBC) lacks effective targeted therapies, posing a significant clinical challenge.
• Chimeric antigen receptor (CAR)-T cell therapy shows promise for solid tumors but faces limitations like on-target/off-tumor toxicities.

Purpose of the Study:

• To identify novel therapeutic targets for triple-negative breast cancer.
• To develop and evaluate ZP4-specific CAR-T cells for TNBC treatment.

Main Methods:

• Comprehensive bioinformatic analysis of public RNA and proteomic data to identify potential TNBC targets.
• Generation of ZP4-specific monoclonal antibodies and engineering of CAR constructs using scFv domains.
• Assessment of ZP4 CAR-T cell efficacy in TNBC cell lines and patient-derived xenograft (PDX) models.

Main Results:

• Zona pellucida glycoprotein 4 (ZP4) was identified as a novel target, expressed in a subset of TNBC samples and PDX models, with restricted expression in oocytes.
• Engineered ZP4 CAR-T cells demonstrated significant efficacy against ZP4-expressing TNBC cells and PDX models.
• Variations in the scFv antigen binding domain were found to critically impact CAR-T cell function.

Conclusions:

• ZP4 represents a promising and specific target for the immunotherapy of triple-negative breast cancer.
• ZP4-targeted CAR-T cell therapy holds potential for treating TNBC, warranting further clinical investigation.
• Understanding the influence of scFv variations is crucial for optimizing CAR-T cell design and efficacy.